User profiles for S. Stelloo
Suzan StellooRadboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands Verified email at science.ru.nl Cited by 925 |
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is
controversial, constraining implementation of AR-directed therapies. Using a diverse, …
controversial, constraining implementation of AR-directed therapies. Using a diverse, …
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
…, J Bishop, M Hoogstraat, A Talal, S Stelloo… - Nature cell …, 2021 - nature.com
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
[HTML][HTML] RNA-centric methods: toward the interactome of specific RNA transcripts
RNA–protein interactions play an important role in numerous cellular processes in health
and disease. In recent years, the global RNA-bound proteome has been extensively studied, …
and disease. In recent years, the global RNA-bound proteome has been extensively studied, …
[HTML][HTML] Integrative epigenetic taxonomy of primary prostate cancer
… RNA was extracted using the AllPrep DNA/RNA universal kit (Qiagen) according to the
manufacturer’s instruction with Qiagen’s QIAcube robot. RNA quantity and quality were assessed …
manufacturer’s instruction with Qiagen’s QIAcube robot. RNA quantity and quality were assessed …
[PDF][PDF] CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis
…, LD Deonarine, BD Robinson, D Huang, S Stelloo… - Cancer Cell, 2019 - cell.com
Deletion of the gene encoding the chromatin remodeler CHD1 is among the most common
alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and …
alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and …
[HTML][HTML] Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers
… Collecting the primary tumor(s) as well as the metastases during disease progression and
at time of death is of great interest, enabling the identification of AR cistrome characteristics of …
at time of death is of great interest, enabling the identification of AR cistrome characteristics of …
Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis
Androgen receptor (AR) is a key player in prostate cancer development and progression. Here
we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to …
we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to …
Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐and CXCL8‐mediated cancer cell migration
…, MHM Melis, J van Burgsteden, S Stelloo… - Molecular …, 2018 - Wiley Online Library
Fibroblasts are abundantly present in the prostate tumor microenvironment (TME), including
cancer‐associated fibroblasts (CAFs) which play a key role in cancer development. …
cancer‐associated fibroblasts (CAFs) which play a key role in cancer development. …
Androgen receptor profiling predicts prostate cancer outcome
S Stelloo, E Nevedomskaya… - EMBO molecular …, 2015 - embopress.org
… Hierarchical clustering of Stelloo et al's (this manuscript) and Chen et al's data Heatmap of
the correlation between the ChIP-seq data from Stelloo et al and Chen et al based on the 339 …
the correlation between the ChIP-seq data from Stelloo et al and Chen et al based on the 339 …
Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence
S Linder, M Hoogstraat, S Stelloo, N Eickhoff… - Cancer discovery, 2022 - AACR
Understanding how prostate cancers adapt to AR-targeted interventions is critical for identifying
novel drug targets to improve the clinical management of treatment-resistant disease. …
novel drug targets to improve the clinical management of treatment-resistant disease. …